{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Pontiroli AE"],"pubmed_abstract":["Glucagon (traditional kits for intramuscular administration, Glucagon and Glucagen), although recommended as a remedy for severe hypoglycemia (SH), has been reported to be under-utilized, likely because of technical problems. The aims of this study were to evaluate the use of glucagon in persons with type 1 diabetes in several countries, and to investigate if the availability of new ready-to-use glucagons (Baqsimi, Gvoke, Zegalogue, years 2019 to 2021) has expanded the overall use of glucagon. The source of data was IQVIA-MIDAS (units of glucagon sold), while data on persons with type 1 diabetes in countries were derived from IDF Diabetes Atlas. The use of glucagon has been steady from 2014 to 2019, with a small but significant increase from 2019 to 2021, paradoxically only in countries wh"],"journal":["Diabetology & metabolic syndrome"],"pagination":["193"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9780089"],"repository":["biostudies-literature"],"pubmed_title":["Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons."],"pmcid":["PMC9780089"],"pubmed_authors":["Rizzo M","Tagliabue E","Pontiroli AE"],"additional_accession":[]},"is_claimable":false,"name":"Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons.","description":"Glucagon (traditional kits for intramuscular administration, Glucagon and Glucagen), although recommended as a remedy for severe hypoglycemia (SH), has been reported to be under-utilized, likely because of technical problems. The aims of this study were to evaluate the use of glucagon in persons with type 1 diabetes in several countries, and to investigate if the availability of new ready-to-use glucagons (Baqsimi, Gvoke, Zegalogue, years 2019 to 2021) has expanded the overall use of glucagon. The source of data was IQVIA-MIDAS (units of glucagon sold), while data on persons with type 1 diabetes in countries were derived from IDF Diabetes Atlas. The use of glucagon has been steady from 2014 to 2019, with a small but significant increase from 2019 to 2021, paradoxically only in countries wh","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-07T17:57:56.226Z","creation":"2025-04-05T15:41:40.393Z"},"accession":"S-EPMC9780089","cross_references":{"pubmed":["36550552"],"doi":["10.1186/s13098-022-00950-6"]}}